Patent applications published 8 September 2010
Selected patent applications from the weekly European Patents Bulletin
- Macrocyclic oximyl hepatitis C serine protease inhibitors
Enanta Pharmaceuticals 2224801*
- Spiropiperidines for use as tryptase inhibitors
Janssen Pharmaceutica 2224803*
- Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors
BiPar Sciences 2224804*
- Pharmaceutical compsn
Alpharma Pharmaceuticals 2224805*
- Pharmaceutical compsn
Alpharma Pharmaceuticals 2224806*
- Methods for stereoselective reduction
Infinity Pharmaceuticals 2224807*
- Pharmaceutical compsn
Alpharma Pharmaceuticals 2224808*
- Zolylmethyloxiranes, use thereof and agents containing the same
BASF 2224812*
- Combinations of fungicidal azoles and pyrion compounds
Janssen Pharmaceutica 2224814*
- Silver nanoparticles with specific surface area and a method for producing them
Janssen Pharmaceutica 2224815*
- Intravesical compsns with valrubicin for the treatment of bladder cancer
Endo Pharmaceutical Solutions 2224904*
- Multi-phasic, nano-structured compsns, containing a combination of a fibrate and a statin
Novavax 2224905*
- A method for producing adapalene gels
Galderma Research & Development 2224906*
- Pharmaceutical formulation containing lipophilic drugs and milk as a solubilising/dispersing agent and method for the preparation thereof
Pharmathen 2224907*
- Compsns containing at least one naphthoic acid derivative, benzoul peroxide and at least one film-forming agent, methods for preparing same and uses thereof
Galderma Research & Development 2224908*
- Stabilisation of liquid-formulated factor VII(A) polypeptides by aldehyde-containing compounds
Novo Nordisk Health Care 2224909*
- Method and compsn for treating pulmonary haemorrhage
JBS United 2224911*
- Improved compsns and methods for the delivery of nucleic acids
Tekmira Pharmaceuticals; The University of British Columbia; Alnylam Pharmaceuticals 2224912*
- Improved formulations and methods for lyophilisation and lyophilisates provided thereby
Remedy Pharmaceuticals 2224913*
- Rhein or diacerein compsns
Wockhardt Research Centre 2226914*
- Pharmaceutical compsn
Alpharma Pharmaceuticals 2228915*
- Carrier particle for a microorganism or subunit thereof, pharmaceutical compsn comprising such particles, method for preparation of this compsn and its use in the treatment of animals
Intervet International 2228916*
- Compsns comprising nicotinic agonists and methods of using the same
Neuroderm 2225917*
- Methods and compsns for the treatment of cancer, tumours, and tumour-related disorders
Tragara Pharmaceuticals 2224919*
- Process for making macrocyclic oximyl hepatitis C protease inhibitors
Enanta Pharmaceuticals 2228920*
- Modulation of the immune response
The Brigham & Women’s Hospital 2224931*
- Use of phthalamide and/or sulphonamide derivatives in the treatment of diseases which require reducing the TNF-levels and an exogenous source of nitric oxide, phthalam derivatives, sulphonamide derivatives, and a method for obtaining a sulphonamide derivative
Universidade Estudual De Campinas-Unicamp 2224922*
- Compsns and methods for inhibiting cytochrome P450 2D6
Sequoia Pharmaceuticals 2224923*
- Compsns and methods for treating cystic fibrosis
Revalesio Corp 2224924*
- Compounds for use in treatment of cancer
Pledpharma 2224925*
- Prolyl hydroxylase inhibitors
GlaxoSmithKline 2224926*
- Pterin analogue for treating BH4 responsive condition
BioMarin Pharmaceuticals 2224927*
- Novel SEH inhibitors and their use
GlaxoSmithKline 2224928*
- Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
Janssen Pharmaceutica 2224929*
- Compsns comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
Nestec 2224930*
- Beta glycolipids for the treatment of calcification related degenerative disorders
Hadasit Medical Research Services and Development 2224931*
- Cancer treatment using COX-2 inhibitor and antimetabolite combinations
Tragara Pharmaceuticals 2224932*
- Conjugated beta-1,3-linked glucans
Novartis 2224933*
- Human bone-forming cells in the treatment of inflammatory rheumatic diseases
Bone Therapeutics 2224934*
- Method for decreasing abdominal girth by administering a bifidobacterium bacteria
Compagnie Gervais Danone 2224935*
- Use of a L-casei strain, for the preparation of a compsn for inhibiting mast cell activation
Institut Pasteur; Compagnie Gervais Danone 2224936*
- Compsn for preventing and treating metabolic diseases comprising the extract of Lysimachiae foenum-graeci herba
BRNScience 2224937*
- Extract of piper betel leaves for the treatment of human malignancies by inducing oxidative stress
Council of Scientific and Industrial Research, India 2224939*
- Preparations with rosehip extracts and method of producing rosehip extracts
Finzelberg 2224939*